Daliborka Bursac
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Daliborka Bursac has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Bojan Zaric
Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
6 shared publications - Tomi Kovacevic
Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
5 shared publications - Vladimir Stojšić
Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
5 shared publications - Darijo Bokan
Faculty of Medicine, University of Novi Sad, 21000 Novi Sad, Serbia
3 shared publications - Christoforos Kosmidis
School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
2 shared publications - Chrysanthi Sardeli
Department of Clinical Pharmacology, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece
2 shared publications
Latest Publications
- Open Access
- 29 October 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (21) , 2734
Nodule Characteristics, Clinical Risk Factors, and Radiologist Experience as Predictors of Positive Baseline LDCT Screening Results
Background/Objectives: Early detection of lung cancer through low-dose computed tomography (LDCT) significantly improves patient outcomes. Identifying predictors of positive baseline LDCT findings can optimize screening programs and cost-effectiveness, particularly in regional settings. Methods: We conducted a retrospective analysis of baseline LDCT screenings performed in 2024 at three sites in Vojvodina, Serbia. Eligible participants were adults aged 50–74 years with a significant smoking history. Lung nodules were evaluated using the Lung-RADS system. Sociodemographic, clinical, and nodule-related variables, as well as radiologist experience (>10 vs. <10 years), were assessed. Multivariable logistic regression identified independent predictors of positive LDCT outcomes (Lung-RADS 3, 4A, 4B, 4X). Results: Overall, 17.6% (613/3479) of participants had positive baseline LDCT findings. Multivariable analysis showed that nodule type (semi-solid: OR = 4.01, 95% CI: 1.46–11.01; solid: OR = 8.86, 95% CI: 4.53–17.32), nodule morphology (smooth: OR = 0.42, 95% CI: 0.22–0.81; perifissural: OR = 0.16, 95% CI: 0.08–0.33; endobronchial: OR = 47.99, 95% CI: 12.35–186.58), nodule diameter (OR = 1.83 per mm, 95% CI: 1.71–1.96), presence of COPD (OR = 1.95, 95% CI: 1.23–3.08), age (OR = 1.02 per year, 95% CI: 1.00–1.04), and radiologist <10 years working experience (OR = 1.47, 95% CI: 1.23–3.08) were independent predictors of positivity. Conclusions: Baseline LDCT positivity is influenced by nodule characteristics, patient sociodemographic and clinical factors, and radiologist experience. These findings can inform targeted screening strategies in high-risk populations.
- 29 October 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (21) , 2734
Open AccessNodule Characteristics, Clinical Risk Factors, and Radiologist Experience as Predictors of Positive Baseline LDCT Screening Results
Background/Objectives: Early detection of lung cancer through low-dose computed tomography (LDCT) significantly improves patient outcomes. Identifying predictors of positive baseline LDCT findings can optimize screening programs and cost-effectiveness, particularly in regional settings. Methods: We conducted a retrospective analysis of baseline LDCT screenings performed in 2024 at three sites in Vojvodina, Serbia. Eligible participants were adults aged 50–74 years with a significant smoking history. Lung nodules were evaluated using the Lung-RADS system. Sociodemographic, clinical, and nodule-related variables, as well as radiologist experience (>10 vs. <10 years), were assessed. Multivariable logistic regression identified independent predictors of positive LDCT outcomes (Lung-RADS 3, 4A, 4B, 4X). Results: Overall, 17.6% (613/3479) of participants had positive baseline LDCT findings. Multivariable analysis showed that nodule type (semi-solid: OR = 4.01, 95% CI: 1.46–11.01; solid: OR = 8.86, 95% CI: 4.53–17.32), nodule morphology (smooth: OR = 0.42, 95% CI: 0.22–0.81; perifissural: OR = 0.16, 95% CI: 0.08–0.33; endobronchial: OR = 47.99, 95% CI: 12.35–186.58), nodule diameter (OR = 1.83 per mm, 95% CI: 1.71–1.96), presence of COPD (OR = 1.95, 95% CI: 1.23–3.08), age (OR = 1.02 per year, 95% CI: 1.00–1.04), and radiologist <10 years working experience (OR = 1.47, 95% CI: 1.23–3.08) were independent predictors of positivity. Conclusions: Baseline LDCT positivity is influenced by nodule characteristics, patient sociodemographic and clinical factors, and radiologist experience. These findings can inform targeted screening strategies in high-risk populations.
- Open Access
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Glasnik javnog zdravlja
- Vol. 99 (1) , 1-21
Lung cancer incidence and mortality, primary and secondary prevention: Where are we?
The incidence and mortality of lung cancer (LC) have shown significant trends in recent decades, with marked differences in gender patterns. This study is based on a literature review, analysis of trends in LC incidence and mortality, and evaluation of health-educational measures for smoking prevention in the Mačva District (MD) and Central Serbia (CS). Data were obtained from the Serbian Cancer Registry (2003-2022) and the Health-Educational Activity Protocol of the Institute of Public Health Šabac (2007-2019). The first part includes a literature review (Web of Science, PubMed, Google Scholar) using key terms such as "lung cancer", "incidence", "mortality", "smoking" and "prevention". The second part utilizes data from the Serbian Cancer Registry, analysed using standardized incidence and mortality rates (the Segi-Doll methodology). The third part evaluates health-educational activities in MD. Trends were examined using descriptive statistics and linear trend analysis, with comparisons conducted using Student's t-test for independent samples. The average incidence and mortality rates of LC in MD for the period 2003-2022 were 63.8 and 52.6/100,000 in men, and 19.3 and 15.4/100,000 in women. The male-to-female ratio in incidence decreased from 4.5 (2003) to 2.6 (2022), and in mortality from 3.2 to 2.3. In CS, from 2000 to 2019, the average incidence and mortality rates in men were 63.5 and 50.0/100,000, and in women, 20.7 and 16.1/100,000. The male-to-female ratio in incidence decreased from 3.8 to 2.6, and in mortality from 3.3 to 2.4. The annual incidence increase in women was 3.1% in MD (R²=0.64) and 2.8% in CS (R²=0.78), while mortality increased by 0.9% in MD (R²=0.64) and 1.7% in CS (R²=0.68). In MD, incidence and mortality in men slightly decreased by 0.6% per year, while in CS, incidence stagnated, and mortality decreased by 0.8% per year. The differences in rates between MD and CS were not statistically significant. Preventive measures covered 25,150 individuals, with coverage increasing by 8.3% per year (R²=0.69), but activities were suspended during the COVID-19 pandemic. LC incidence and mortality have decreased in men but continue to rise in women. Decreasing smoking prevalence and implementing LDCT screening are crucial.
- 1 January 2025
- Published by Centre for Evaluation in Education and Science (CEON/CEES) in Glasnik javnog zdravlja
- Vol. 99 (1) , 1-21
Open AccessLung cancer incidence and mortality, primary and secondary prevention: Where are we?
The incidence and mortality of lung cancer (LC) have shown significant trends in recent decades, with marked differences in gender patterns. This study is based on a literature review, analysis of trends in LC incidence and mortality, and evaluation of health-educational measures for smoking prevention in the Mačva District (MD) and Central Serbia (CS). Data were obtained from the Serbian Cancer Registry (2003-2022) and the Health-Educational Activity Protocol of the Institute of Public Health Šabac (2007-2019). The first part includes a literature review (Web of Science, PubMed, Google Scholar) using key terms such as "lung cancer", "incidence", "mortality", "smoking" and "prevention". The second part utilizes data from the Serbian Cancer Registry, analysed using standardized incidence and mortality rates (the Segi-Doll methodology). The third part evaluates health-educational activities in MD. Trends were examined using descriptive statistics and linear trend analysis, with comparisons conducted using Student's t-test for independent samples. The average incidence and mortality rates of LC in MD for the period 2003-2022 were 63.8 and 52.6/100,000 in men, and 19.3 and 15.4/100,000 in women. The male-to-female ratio in incidence decreased from 4.5 (2003) to 2.6 (2022), and in mortality from 3.2 to 2.3. In CS, from 2000 to 2019, the average incidence and mortality rates in men were 63.5 and 50.0/100,000, and in women, 20.7 and 16.1/100,000. The male-to-female ratio in incidence decreased from 3.8 to 2.6, and in mortality from 3.3 to 2.4. The annual incidence increase in women was 3.1% in MD (R²=0.64) and 2.8% in CS (R²=0.78), while mortality increased by 0.9% in MD (R²=0.64) and 1.7% in CS (R²=0.68). In MD, incidence and mortality in men slightly decreased by 0.6% per year, while in CS, incidence stagnated, and mortality decreased by 0.8% per year. The differences in rates between MD and CS were not statistically significant. Preventive measures covered 25,150 individuals, with coverage increasing by 8.3% per year (R²=0.69), but activities were suspended during the COVID-19 pandemic. LC incidence and mortality have decreased in men but continue to rise in women. Decreasing smoking prevalence and implementing LDCT screening are crucial.
- Open Access
Efficacy of Atezolizumab in Subsequent Lines of Therapy for NSCLC Patients: Insights from Real-World Data
Immune checkpoint inhibitors (ICIs) like atezolizumab have improved outcomes in advanced non-small cell lung cancer (NSCLC) patients, especially in the second-line setting after progression on platinum-based chemotherapy. However, access to ICIs remains limited in many developing nations. This study evaluated the efficacy of atezolizumab as a second-line versus later-line treatment for advanced NSCLC patients in Serbia. Methods: This retrospective study involved 147 advanced NSCLC patients treated with atezolizumab following progression on prior platinum-based chemotherapy at two academic centers in Serbia. Data on demographics and clinical, pathological, and molecular characteristics were collected. Median progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and multivariable Cox proportional hazards regression identified outcome predictors. Results: The median PFS was 7.13 months, and median OS was 38.6 months. The overall response rate (ORR) was 15%, with a disease control rate (DCR) of 57.9%. No significant PFS differences were observed between patients treated with atezolizumab in the second line versus later lines. Patients with good performance status (ECOG 0–1) had significantly better PFS compared to those with poorer status (12.03 vs. 1.63 months, p < 0.0001). Conclusions: Atezolizumab is effective in both second-line and later-line settings for advanced NSCLC, particularly in patients with good performance status. This highlights the importance of patient selection based on performance status, as well as the need for wider access to ICIs in resource-limited regions.
Open AccessEfficacy of Atezolizumab in Subsequent Lines of Therapy for NSCLC Patients: Insights from Real-World Data
Immune checkpoint inhibitors (ICIs) like atezolizumab have improved outcomes in advanced non-small cell lung cancer (NSCLC) patients, especially in the second-line setting after progression on platinum-based chemotherapy. However, access to ICIs remains limited in many developing nations. This study evaluated the efficacy of atezolizumab as a second-line versus later-line treatment for advanced NSCLC patients in Serbia. Methods: This retrospective study involved 147 advanced NSCLC patients treated with atezolizumab following progression on prior platinum-based chemotherapy at two academic centers in Serbia. Data on demographics and clinical, pathological, and molecular characteristics were collected. Median progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan–Meier method, and multivariable Cox proportional hazards regression identified outcome predictors. Results: The median PFS was 7.13 months, and median OS was 38.6 months. The overall response rate (ORR) was 15%, with a disease control rate (DCR) of 57.9%. No significant PFS differences were observed between patients treated with atezolizumab in the second line versus later lines. Patients with good performance status (ECOG 0–1) had significantly better PFS compared to those with poorer status (12.03 vs. 1.63 months, p < 0.0001). Conclusions: Atezolizumab is effective in both second-line and later-line settings for advanced NSCLC, particularly in patients with good performance status. This highlights the importance of patient selection based on performance status, as well as the need for wider access to ICIs in resource-limited regions.
- Open Access
- 16 June 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (6) , 3350-3360
Attitudes toward Death among Health Care Professionals in the Balkan Region
Background and Objectives: Death is an unavoidable experience in any person’s life and affects not only the dying person but also their caregivers. The dying process has been displaced from homes to health care facilities in the majority of cases. Facing death and dying has become an everyday life of health care professionals (HCP), especially in palliative care (PC) settings. This study aimed to investigate the death attitudes among HCPs in Serbia. Materials and Methods: The Serbian version of the Death Attitude Profile-Revised (DAP-RSp) was used as a measurement instrument. Results: The average age of the 180 included participants was 42.2 ± 9.9 years; the majority were females (70.0%), with more than 10 years of working experience (73.0%), physicians (70.0%) and those working in a non-oncological (non-ONC) field (57.78%). The mean total score of DAP-RSp was 124.80 ± 22.44. The highest mean score was observed in the neutral acceptance dimension (NA) (5.82 ± 0.90) and lowest in the Escape acceptance (EA) (2.57 ± 1.21). Higher negative death attitudes were reported among nurses compared to physicians (p = 0.002). Statistically significant differences were observed in the fear of death (FD) and death avoidance (DA) domains, favoring PC specialists and oncologists (p = 0.004; p = 0.015). Physicians working in Oncology (ONC) showed lower FD values (p = 0.001) compared to non-ONC departments. Conclusions: Attitudes toward death among HCPs are of great importance for the well-being of both HCPs and patients. Negative attitudes can lead to deficient care. The fear of death is highly represented among Serbian HCPs working in non-ONC fields, including both nurses and physicians. This study emphasizes the need for further research to comprehensively explore and understand HCPs’ attitudes toward death. This research highlights the need for the development of an educational curriculum across all levels of medical education, aimed at overcoming the fear of death and enhancing coping strategies, which will improve the care for patients diagnosed with terminal illnesses.
- 16 June 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (6) , 3350-3360
Open AccessAttitudes toward Death among Health Care Professionals in the Balkan Region
Background and Objectives: Death is an unavoidable experience in any person’s life and affects not only the dying person but also their caregivers. The dying process has been displaced from homes to health care facilities in the majority of cases. Facing death and dying has become an everyday life of health care professionals (HCP), especially in palliative care (PC) settings. This study aimed to investigate the death attitudes among HCPs in Serbia. Materials and Methods: The Serbian version of the Death Attitude Profile-Revised (DAP-RSp) was used as a measurement instrument. Results: The average age of the 180 included participants was 42.2 ± 9.9 years; the majority were females (70.0%), with more than 10 years of working experience (73.0%), physicians (70.0%) and those working in a non-oncological (non-ONC) field (57.78%). The mean total score of DAP-RSp was 124.80 ± 22.44. The highest mean score was observed in the neutral acceptance dimension (NA) (5.82 ± 0.90) and lowest in the Escape acceptance (EA) (2.57 ± 1.21). Higher negative death attitudes were reported among nurses compared to physicians (p = 0.002). Statistically significant differences were observed in the fear of death (FD) and death avoidance (DA) domains, favoring PC specialists and oncologists (p = 0.004; p = 0.015). Physicians working in Oncology (ONC) showed lower FD values (p = 0.001) compared to non-ONC departments. Conclusions: Attitudes toward death among HCPs are of great importance for the well-being of both HCPs and patients. Negative attitudes can lead to deficient care. The fear of death is highly represented among Serbian HCPs working in non-ONC fields, including both nurses and physicians. This study emphasizes the need for further research to comprehensively explore and understand HCPs’ attitudes toward death. This research highlights the need for the development of an educational curriculum across all levels of medical education, aimed at overcoming the fear of death and enhancing coping strategies, which will improve the care for patients diagnosed with terminal illnesses.
- Open Access
Effective Differences between 2D and 3D Planned Brachytherapy in Lung Cancer: An Institutional Retrospective Study
Background and Objectives: Advanced lung cancer is usually manifested by endoluminal tumor propagation, resulting in central airway obstruction. The objective of this study is to compare the high dose rate brachytherapy treatment outcomes in non-small-cell lung cancer (NSCLC) depending on the treatment planning pattern—two-dimension (2D) or three-dimension (3D) treatment planning. Materials and Methods: The study was retrospective and two groups of patients were compared in it (a group of 101 patients who underwent 2D planned high-dose-rate endobronchial brachytherapy (HDR-EBBT) in 2017/18 and a group of 83 patients who underwent 3D planned HDR-EBBT between January 2021 and June 2023). Results: In the group of 3D planned brachytherapy patients, there was a significant improvement in terms of loss of symptoms of bronchial obstruction (p = 0.038), but no improvement in terms of ECOG PS (European Cooperative Oncology Group Performance Status) of the patient (p = 0.847) and loss of lung atelectasis (if there was any at the beginning of the disease) (p = 0.781). Two-year overall survival and time-to-progression periods were similar for both groups of patients (p = 0.110 and 0.154). Fewer treatment complications were observed, and 91.4% were in 3D planned brachytherapy (BT) patients. Conclusions: Three-dimensionally planned HDR-EBBT is a suggestive, effective palliative method for the disobstruction of large airways caused by endobronchial lung tumor growth. Independent or more often combined with other types of specific oncological treatment, it certainly leads to the loss of symptoms caused by bronchial obstruction and the improvement of the quality of life of patients with advanced NSCLC. Complications of the procedure with 3D planning are less compared to 2D planned HDR-EBBT.
Open AccessEffective Differences between 2D and 3D Planned Brachytherapy in Lung Cancer: An Institutional Retrospective Study
Background and Objectives: Advanced lung cancer is usually manifested by endoluminal tumor propagation, resulting in central airway obstruction. The objective of this study is to compare the high dose rate brachytherapy treatment outcomes in non-small-cell lung cancer (NSCLC) depending on the treatment planning pattern—two-dimension (2D) or three-dimension (3D) treatment planning. Materials and Methods: The study was retrospective and two groups of patients were compared in it (a group of 101 patients who underwent 2D planned high-dose-rate endobronchial brachytherapy (HDR-EBBT) in 2017/18 and a group of 83 patients who underwent 3D planned HDR-EBBT between January 2021 and June 2023). Results: In the group of 3D planned brachytherapy patients, there was a significant improvement in terms of loss of symptoms of bronchial obstruction (p = 0.038), but no improvement in terms of ECOG PS (European Cooperative Oncology Group Performance Status) of the patient (p = 0.847) and loss of lung atelectasis (if there was any at the beginning of the disease) (p = 0.781). Two-year overall survival and time-to-progression periods were similar for both groups of patients (p = 0.110 and 0.154). Fewer treatment complications were observed, and 91.4% were in 3D planned brachytherapy (BT) patients. Conclusions: Three-dimensionally planned HDR-EBBT is a suggestive, effective palliative method for the disobstruction of large airways caused by endobronchial lung tumor growth. Independent or more often combined with other types of specific oncological treatment, it certainly leads to the loss of symptoms caused by bronchial obstruction and the improvement of the quality of life of patients with advanced NSCLC. Complications of the procedure with 3D planning are less compared to 2D planned HDR-EBBT.
- Open Access
- 1 January 2022
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 79 (5) , 481-487
Mortality of COVID-19 pneumonia during anticancer treatment in lung cancer patients
Background/Aim: The COVID-19 pandemic has multiple impacts on the management of cancer patients. Treatment of malignancies, including chemotherapy, targeted therapy, immunotherapy and radiotherapy, can suppress the immune system and lead to the development of severe complications of COVID-19 infection. The aim of this study was to determine the mortality of lung cancer (LC) patients, in whom the COVID-19 infection was confirmed during active antitumor treatment. Methods: This retrospective study was conducted at the Institute for Pulmonary Diseases of Vojvodina. All patients included in the study underwent active anticancer treatment at the time of diagnosis of COVID-19. SARS-CoV-2 infection was determined with polymerase chain reaction test (PCR). Patient data were collected using the institutional database and observed period was from November 20, 2020 to June 5, 2021. Statistical analysis of the derived patient’s data using the multivariate and univariate testing. Results: Out of total 828 observed COVID-19 hospitalized patients 81 were LC patient on active antitumor treatment. Patients were predominantly male (67.9%), smokers (55.6%), 66.47 years old (range 43-83). Majority of patients (50.6%) were Eastern Cooperative Oncology Group performance status (ECOG PS) 1 and 83.9% had at least one comorbidity. The most common comorbidities were arterial hypertension (66.7%), chronic obstructive pulmonary disease (COPD) (28.4%) and diabetes (21%). Obesity, congestive heart failure and other cardiovascular diseases were present in 11%, 6.2% and 7.4% of patients. The most common was adenocarcinoma (33.3%), followed by squamous (30.9%) and small-cell lung cancer (24.7%). Predominantly 63% of the patients were in stage III of disease and 33.3% were in stage IV. Metastases were most commonly present in the contralateral lung/pleura (14.8%), brain (6.2%), bone (3.7%) and liver (3.7%). Systemic anticancer therapy was applied in 37/81 patients (45.6%), chest radiotherapy in 35/81 (43.2%), concurrent chemoradiotherapy in 1/81 (1.2%) and other types of radiotherapy in 8/81 patients (9.87%). The most common forms of systemic therapy were chemotherapy (35.8%), immunotherapy (7.4%) and targeted therapy (2.4%) patients. Most common chemotherapy was cisplatin-based regiment applied in 34.6% of patients. The mortality from COVID-19 was 19.8%. The statistically significance in relation to the type of treatment was not observed (p = 0.973). Statistical significance was observed between mortality and ECOG PS (p = 0.011). Conclusions: LC patients are dependent on antitumor treatment and at the same time highly susceptible to potential infection. In this study we did not find statistically significant differences in mortality related to the type of antitumor treatment in COVID-19 positive LC patients. Further detailed research on larger scale is needed to be performed in order to explore the effects of SARS-CoV-2 on cancer patients. All possible methods of protection against SARS-CoV-2 virus should be performed in order to minimize the risk of infection in all but especially in immunocompromised cancer patients.
- 1 January 2022
- Published by National Library of Serbia in Vojnosanitetski Pregled
- Vol. 79 (5) , 481-487
Open AccessMortality of COVID-19 pneumonia during anticancer treatment in lung cancer patients
Background/Aim: The COVID-19 pandemic has multiple impacts on the management of cancer patients. Treatment of malignancies, including chemotherapy, targeted therapy, immunotherapy and radiotherapy, can suppress the immune system and lead to the development of severe complications of COVID-19 infection. The aim of this study was to determine the mortality of lung cancer (LC) patients, in whom the COVID-19 infection was confirmed during active antitumor treatment. Methods: This retrospective study was conducted at the Institute for Pulmonary Diseases of Vojvodina. All patients included in the study underwent active anticancer treatment at the time of diagnosis of COVID-19. SARS-CoV-2 infection was determined with polymerase chain reaction test (PCR). Patient data were collected using the institutional database and observed period was from November 20, 2020 to June 5, 2021. Statistical analysis of the derived patient’s data using the multivariate and univariate testing. Results: Out of total 828 observed COVID-19 hospitalized patients 81 were LC patient on active antitumor treatment. Patients were predominantly male (67.9%), smokers (55.6%), 66.47 years old (range 43-83). Majority of patients (50.6%) were Eastern Cooperative Oncology Group performance status (ECOG PS) 1 and 83.9% had at least one comorbidity. The most common comorbidities were arterial hypertension (66.7%), chronic obstructive pulmonary disease (COPD) (28.4%) and diabetes (21%). Obesity, congestive heart failure and other cardiovascular diseases were present in 11%, 6.2% and 7.4% of patients. The most common was adenocarcinoma (33.3%), followed by squamous (30.9%) and small-cell lung cancer (24.7%). Predominantly 63% of the patients were in stage III of disease and 33.3% were in stage IV. Metastases were most commonly present in the contralateral lung/pleura (14.8%), brain (6.2%), bone (3.7%) and liver (3.7%). Systemic anticancer therapy was applied in 37/81 patients (45.6%), chest radiotherapy in 35/81 (43.2%), concurrent chemoradiotherapy in 1/81 (1.2%) and other types of radiotherapy in 8/81 patients (9.87%). The most common forms of systemic therapy were chemotherapy (35.8%), immunotherapy (7.4%) and targeted therapy (2.4%) patients. Most common chemotherapy was cisplatin-based regiment applied in 34.6% of patients. The mortality from COVID-19 was 19.8%. The statistically significance in relation to the type of treatment was not observed (p = 0.973). Statistical significance was observed between mortality and ECOG PS (p = 0.011). Conclusions: LC patients are dependent on antitumor treatment and at the same time highly susceptible to potential infection. In this study we did not find statistically significant differences in mortality related to the type of antitumor treatment in COVID-19 positive LC patients. Further detailed research on larger scale is needed to be performed in order to explore the effects of SARS-CoV-2 on cancer patients. All possible methods of protection against SARS-CoV-2 virus should be performed in order to minimize the risk of infection in all but especially in immunocompromised cancer patients.
- Open Access
- 31 December 2021
- Vol. 47 (4) , 507-515
Long Term Respiratory Follow-Up for COVID-19 Patients a Multicenter Study
Background: The first wave of the COVID-19 pandemic initiated officially in October 2020. Since then several observations have been made regarding the disease and its symptoms. Patients and Methods: We included eighty seven in our observational study. Our main aim was to investigate their long term respiratory follow-up in correlation with their initial radiological and laboratory findings and values. The nose swab PCR test for COVID-19 was used for diagnosis. Patients were monitored at 3 and 6 months after their hospital reception whereas basic parameters of health condition (smoking, PO2, SPO2, WBC, CXR, CRP, intercurrent findings, days of nursing, colchicine administration) in joint with gender and age were recorded. Results: Males seem more susceptible to the viral disease than females in a ratio 1,8:1. The parameters FEV1 and FVC (as % relative changes) were not affected, apart from the DLCO to which CRP (in loge+1 transformation) and SPO2 showed a statistically significant effect. Conclusion: None of these patients were intubated, or admitted to the intensive care unit. The respiratory function is affected by the virus and the effect is reversed within the first three months. Males are more affected and the radiological and laboratory findings are associated with the respiratory functions.
- 31 December 2021
- Vol. 47 (4) , 507-515
Open AccessLong Term Respiratory Follow-Up for COVID-19 Patients a Multicenter Study
Background: The first wave of the COVID-19 pandemic initiated officially in October 2020. Since then several observations have been made regarding the disease and its symptoms. Patients and Methods: We included eighty seven in our observational study. Our main aim was to investigate their long term respiratory follow-up in correlation with their initial radiological and laboratory findings and values. The nose swab PCR test for COVID-19 was used for diagnosis. Patients were monitored at 3 and 6 months after their hospital reception whereas basic parameters of health condition (smoking, PO2, SPO2, WBC, CXR, CRP, intercurrent findings, days of nursing, colchicine administration) in joint with gender and age were recorded. Results: Males seem more susceptible to the viral disease than females in a ratio 1,8:1. The parameters FEV1 and FVC (as % relative changes) were not affected, apart from the DLCO to which CRP (in loge+1 transformation) and SPO2 showed a statistically significant effect. Conclusion: None of these patients were intubated, or admitted to the intensive care unit. The respiratory function is affected by the virus and the effect is reversed within the first three months. Males are more affected and the radiological and laboratory findings are associated with the respiratory functions.
- Open Access
- 10 May 2021
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 14 (2) , 716-724
Personalized Approach to Tissue and Liquid Biopsy after Failure of First-Line EGFR-TKIs: Is There an Issue When Tissue Is Not the Issue? A Case Series
Traditionally, tissue availability from rebiopsy is a prerequisite for adequate sequencing of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in therapy for advanced-stage lung cancer. Tissue biopsy truly is the gold standard for genetic analyses, but in some cases, such as with inadequate localization of the lesion or a patient’s inadequate performance status, comorbidities, or unwillingness to undergo an invasive procedure, liquid biopsy-based ctDNA analysis can be a noninvasive alternative approach. However, in some cases the gold standard might not shine that much. It is known that tumor heterogeneity or an inadequate amount of tissue might significantly interfere with the results of testing. In this paper, we present cases of patients with a negative tissue biopsy but a positive liquid biopsy which identified coexisting T790M mutation. These results enabled adequate sequencing and treatment with third-line EGFR-TKIs. Such possibilities stress the need to individualize testing for driver mutations in cases where it is clinically highly indicated.
- 10 May 2021
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 14 (2) , 716-724
Open AccessPersonalized Approach to Tissue and Liquid Biopsy after Failure of First-Line EGFR-TKIs: Is There an Issue When Tissue Is Not the Issue? A Case Series
Traditionally, tissue availability from rebiopsy is a prerequisite for adequate sequencing of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in therapy for advanced-stage lung cancer. Tissue biopsy truly is the gold standard for genetic analyses, but in some cases, such as with inadequate localization of the lesion or a patient’s inadequate performance status, comorbidities, or unwillingness to undergo an invasive procedure, liquid biopsy-based ctDNA analysis can be a noninvasive alternative approach. However, in some cases the gold standard might not shine that much. It is known that tumor heterogeneity or an inadequate amount of tissue might significantly interfere with the results of testing. In this paper, we present cases of patients with a negative tissue biopsy but a positive liquid biopsy which identified coexisting T790M mutation. These results enabled adequate sequencing and treatment with third-line EGFR-TKIs. Such possibilities stress the need to individualize testing for driver mutations in cases where it is clinically highly indicated.